A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Financial Summary
| Share Statistics | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $21.3 | $286.3 | 10% |
|
| Shares Out (Mil) | 5.4 | 54.2 | 14% |
|
| Institutional Ownership | 92.5% | 92.8% | 61% |
|
| Float (Mil) | 4.2 | 39.7 | 11% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 47 | 534 | 27% |
|
| Price Change (52-week) |
(48.3%) | 58.7% | 15% |
|
| Growth | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 49.3% | 13.6% | 96% |
|
| Net Income (5yr) | 39.4% | (10.1%) | 91% |
|
| EPS (5yr) | (90.9%) | 16.0% | 1 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 120.0% | (15.6%) | 99% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.560) | ($4.070) | ($2.430) | |
| Month Ago EPS | ($0.560) | ($4.070) | ($2.430) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.560) | ($4.070) | ($2.430) | |
| Year/Year Chg | 502.2% | 1,685% | 978.9% | |
| Financials | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($17) | ($43) | 25% |
|
| EPS (TTM) | ($4.953) | ($1.400) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($31) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $4 | $160 | 5% |
|
| Valuation | NEUP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.72 | 2.77 | 13% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NEUP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 64.2% | 96% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (53.2%) | (47.3%) | 11% |
|
| ROE | (62.9%) | (55.0%) | 13% |
|
| Liabilities to Assets | 15.5% | 29.6% | 10% |
|
| F-Score | 2 | 2 | 7% |
|
Neuphoria Therapeutics Inc. did not pass any screens on 8/20/2026.
